1700629700
[21] Klinkenberg Knol EC, Jansen JM, Festen HP, et al. Double blind multicentre comparison of omeprazole and ranitidine in the treatment of reflux oesophagitis. Lancet, 1987, 1(8529)
:349-351.
1700629701
1700629702
[22] Vantrappen G, Rutgeerts L, Schurmans P, et al. Omeprazole（40mg）is superior to ranitidine in short term treatment of ulcerative reflux esophagitis. Dig Dis Sci, 1988, 33(50)
:523-529.
1700629703
1700629704
[23] Bate CM, Green JR, Axon AT, et al. Omeprazole is more effective than cimetidine in the prevention of recurrenee of GERD associated heartburn and the occurrence of underlying oesophagitis. Aliment Pharmacol Ther, 1998, 12(1)
:41-47.
1700629705
1700629706
[24] Chiba N, De Gara CJ, Wikinson JM, et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta analysis. Gastroenterology, 1997, 112(6)
:1798-1810.
1700629707
1700629708
[25] Castell DO, Richter JE, Robinson M, et al. Efficacy and safety of lansoprazole in the treatment of erosive reflux esophagitis. The Lansoprazole Group. Am J Gastroenterol, 1996, 91(9)
:1749-1757.
1700629709
1700629710
[26] Dekkers CP, Beker JA, Thjodleifsson B, et al. Double blind comparison of raveprazole 20mg vs. omeprazole 20mg in the treatment of erosive or ulcerative gastro oesophageal reflux disease. The European Raveprazole Study Group. Aliment Pharmacol Ther, 1999, 13(1)
:49-57.
1700629711
1700629712
[27] Mee AS, Rowley JL. Rapid symptom relief in reflux oesophagitis: a comparison of lansoprazole and omeprazole. Aliment Pharmacol Ther, 1996, 10(5)
:757-763.
1700629713
1700629714
[28] Jancezewska I, Sagar M, Sjostedt S, et al. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux disease. Scand J Gastroenterol, 1998, 33(12)
:1239-1243.
1700629715
1700629716
[29] Thoring M, Hedenstrom H, Eriksson LS. Rapid effect of lansoprazole intragastric pH: a crossover comparison of omeprazole. Scand J Gastroenterol, 1999, 34(4)
:341.
1700629717
1700629718
[30] Richter JE, Long JF. Cisaprice for gastroesophageal reflux disease: A placebo controlled, double blind study. Am J Gastroenterol, 1995, 90(3)
:423-430.
1700629719
1700629720
[31] Miyamoto M, Haruma K, Takeuchi K, et al. Frequency scale for symptoms of gastroesophageal reflux disease predicts the need for addition of pmkinetics to proton pump inhibitor therapy. J Gastroenteml Hepatol, 2007, 19（online published).
1700629721
1700629722
[32] Hameeteman W. Clinical studies of Sucralfate in reflux esophagitis. The European experience. J Clin Gastroenterol, 1991, 1313
:s16-s20.
1700629723
1700629724
[33] Howden CW, Castell Do, Cohen S, et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med, 1995, 155(14)
:1465-1471.
1700629725
1700629726
[34] Kenneth R, Devault, MD. Overview of medical therapy for GERD. Gastroenterol Clin North Am. 1999, 28(4)
:831-845.
1700629727
1700629728
[35] 王良静，赵岚，姒健敏．不同联合疗法对反流性食管炎的疗效、生活质量和经济投入．中华内科杂志，2002，41(7)
:485-486.
1700629729
1700629730
[36] Vigneris, Termini R, Leandro G, et al. A comparison of five maintenace therapies for reflux esophagitis. N Engl J Med, 1995, 333(17)
:1106-1110.
1700629731
1700629732
[37] Harris RA, Kupprtmann M, Richter JE. Proton pump inhibitors histamine 2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost effectiveness analysis. Am J Gastroenterol, 1997, 92(12)
:2179-2187.
1700629733
1700629734
[38] Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: A cost effectiveness analysis of maintenance proton pump inhibition. Am J Med, 1997, 102
:78-88.
1700629735
1700629736
[39] Robinson MG, Lanza F, Avner D. Effective maintenance treatment of reflux esophagitis with low dose lansoprazole: A randomixed, double blind, placebo controlled trial. Am Inter Med, 124(10)
:859-867.
1700629737
1700629738
[40] Montes CG, Brandal NA, Deliza R, et al. Antireflux surgery followed by bipolar electrocoagulation in the treatment of Barrett’s esophagus. Gastrointest Endosc, 1999, 50(2)
:173-177.
1700629739
1700629740
（姒健敏）
1700629741
1700629742
1700629743
1700629744
1700629746
内科学新进展 第三节 幽门螺杆菌与胃十二指肠疾病
1700629747
1700629748
摘 要 幽门螺杆菌是一种定植于胃黏膜的专性微需氧的革兰阴性菌。幽门螺杆菌是慢性胃炎和消化性溃疡的重要病因。Hp与胃癌的关系也十分密切，世界卫生组织已明确指出Hp为第一类致癌因子。根除Hp的治疗显得尤为重要，但随着抗生素的广泛使用，Hp的耐药性也逐渐增加。除了传统的三联或四联根除方案，对于耐药菌株可改换用左氧氟沙星等抗生素，必要时根据体外Hp培养和药敏试验结果选择抗生素。
1700629749
[
上一页 ]
[ :1.7006297e+09 ]
[
下一页 ]